Core Insights - DEMIRE Deutsche Mittelstand Real Estate AG reported an expected decline in earnings for the first nine months of 2025, primarily due to a targeted reduction in its real estate portfolio [1][5]. Financial Performance - Rental income decreased to EUR 41.4 million compared to EUR 50.6 million in the same period of 2024, reflecting a decline in profit from real estate rentals and write-downs on loans [2][6]. - Earnings before interest and taxes (EBIT) fell to EUR -28.1 million, worsening from EUR -13.8 million in 2024 [2][11]. - Funds from operations (FFO I) after tax, before minorities and interests on shareholder loans dropped to EUR 8.3 million from EUR 23.0 million in the previous year [3][11]. Portfolio and Market Performance - Despite a smaller portfolio, letting performance remained stable at 56,200 m², with 18% from new leases and 82% from contract extensions [4]. - The EPRA vacancy rate increased to 17.4% as of September 30, 2025, up from 15.1% at the end of 2024 [4][12]. - The market value of the DEMIRE portfolio decreased to approximately EUR 735.3 million from EUR 779.3 million [5][12]. Strategic Focus - The company is focusing on operational efficiency and asset management to ensure stable rental performance, while also implementing energy savings in its portfolio [5]. - The net asset value (NAV) per share fell to EUR 1.80 from EUR 2.45, reflecting the negative results for the period [5][12]. - The company confirmed its guidance for 2025, expecting rental income between EUR 52.0 million and EUR 54.0 million, and FFO I between EUR 5.0 million and EUR 7.0 million [6][8]. Liquidity and Debt Management - The average nominal cost of debt remained stable at 4.43% per annum, while net debt decreased to EUR 362.2 million from EUR 371.1 million [6][7]. - Cash and cash equivalents increased to EUR 49.8 million, driven by property sales [7].

Core Insights - McKesson Corporation reported first-quarter fiscal 2026 adjusted EPS of $8.26, exceeding estimates and reflecting a 4.8% year-over-year growth driven by strong operational performance [2][8] - The company plans to spin off its Medical-Surgical Solutions segment to enhance strategic focus and operational efficiency [12][20] Financial Performance - GAAP EPS was $6.25, a decline of 10.7% year-over-year due to increased provisions for bad debts related to Rite Aid's bankruptcy [3] - Revenues reached $97.83 billion, surpassing estimates by 1.8% and showing a 23.4% year-over-year increase, primarily from higher prescription volumes and oncology product distribution [4][8] - Adjusted gross profit was $3.26 billion, up 6.7% year-over-year, while adjusted operating income rose 16.6% to $1.56 billion [14] Segment Analysis - U.S. Pharmaceutical segment revenues totaled $89.95 billion, a 25% increase year-over-year, driven by higher prescription volumes and specialty products [6][9] - International segment revenues were $3.74 billion, up 1% year-over-year, with growth in Canadian pharmaceutical distribution [10] - Medical-Surgical Solutions segment revenues reached $2.7 billion, a 2% increase year-over-year, supported by higher specialty pharmaceutical volumes [11] Strategic Initiatives - The company made two strategic acquisitions, PRISM Vision and Core Ventures, to expand its multi-specialty platform and enhance its provider network [18] - Investments in automation and technology services are expected to improve operational leverage and meet evolving supply-chain requirements [20][21] Future Outlook - McKesson raised its EPS guidance for fiscal 2026 to a range of $37.10-$37.90, reflecting confidence in continued growth despite not providing specific sales outlooks due to the planned spin-off [16] - The upcoming Investor Day in September is anticipated to clarify long-term capital deployment and growth priorities [21]